Adds details on test, background, share price
Aug 27 (Reuters) - The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories ABT.N for about $750 million, a White House spokeswoman said on Thursday.
The portable antigen tests, which can deliver results within 15 minutes and will sell for $5, received emergency use authorization from the U.S. Food and Drug Administration on Wednesday.
The portable test from Abbott is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests.
Antigen tests are cheaper and faster than molecular diagnostic tests, but somewhat more likely to fail to identify positive cases of the virus than lab-based diagnostic tests.
Becton Dickinson and Co BDX.N and Quidel Corp QDEL.O already market antigen tests.
Abbott shares rose 8% to $111.54 in afternoon trading, and the company declined to comment on the latest development.
The White House confirmed an earlier report from Politico.
The U.S. has more COVID-19 testing than most. So why is it falling so short?https://reut.rs/3b2c1yZ
REFILE-UPDATE 1-Abbott wins U.S. authorization for $5 rapid COVID-19 antigen test
(Reporting by Jeff Mason in Washngton; Additional reporting by Ankur Banerjee in Bengaluru; Editing by Dan Grebler and Shounak Dasgupta)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.